NCT01364181

The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

The Impact of Udenafil on Exercise Capacity in Severe COPD Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.

Detailed description

Study design * prospective, single arm, open-label study * Udenafil 50mg qd po for 8 weeks

Conditions

• Dyspnea
• Chronic Obstructive Pulmonary Disease
• Pulmonary Hypertension

Interventions

Type	Name	Description
DRUG	Udenafil	Udenafil 50mg qd po

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-03-01
• Completion: 2011-05-01
• First posted: 2011-06-02
• Last updated: 2011-06-20

Locations

1 site across 1 country: South Korea